Although ErbB3 has been disregarded for several years as a target for cancer therapies recent meta-analysis of ErbB3 expression in several solid tumor demonstrated that increased levels of receptor are constantly associated with worse survival [19]. This evidence concerns the gene ERBB3 and cancer.